New radiation approach for rare cancer aims to reduce side effects
NCT ID NCT06812052
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This early-phase trial is testing whether a shorter, more intense course of radiation is safe for people with a rare cancer called retroperitoneal sarcoma. The study will enroll 6 participants and closely monitor side effects like nausea, vomiting, and diarrhea within 30 days of treatment. The goal is to find a safer way to deliver radiation before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETROPERITONEAL SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital / Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02446, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.